Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Reaps Favipiravir Gains, Progresses COVID-19 Nasal Spray

Emergency India Go-Ahead For NO Spray?

Executive Summary

Strong run on Indian market for Glenmark in fiscal Q1, with the company optimistic of prospects for new introductions including generic Brovana in the US, where it expects close to double-digit growth in Q2. All eyes are also on the launch timelines of a partnered nitric oxide nasal spray for COVID-19.

You may also be interested in...



Cipla Builds On Albuterol Share, Investors Await FY23 US Revenue Delta

Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.

Monroe Site Commercialization ‘Critical’ For Glenmark’s US Step-Up

Glenmark expects its first US manufacturing site to go commercial next year, accelerating growth in that market, while it sets right certain compliance blips back home. The Indian firm is also on course to divest certain non-core assets but notes that bringing in a minority partner for its API unit is not a priority.

Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies

Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel